Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146744
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2005-09-06
Brief Title:
Safety and Immunogenicity of GSK Biologicals Candidate Tuberculosis Vaccine Mtb72FAS02A in Healthy PPD-positive Adults
Sponsor:
Organization:
GlaxoSmithKline
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
38
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: